

## SYMPOSIUM ON TUMOUR HETEROGENEITY

Presenting the projects from the Joint Transnational Call 2014 co-funded by the European Commission on the topic of "Translational research on human tumour heterogeneity to overcome recurrence and resistance to therapy"

**Thursday, October 24th, 2019 | Location: Palazzo Pirelli, Milan, Italy**

### Program

- 09:00 Welcome address
- 09:10 Overview of TRANSCAN and JTC 2014

Presentations of JTC 2014 projects co-funded by the EC

#### First Session

- 9:20 Targeting of resistance in pediatric oncology (TORPEDO)
- 9:40 Overcoming neuroblastoma tumour heterogeneity, resistance and recurrence (ONTHETRRAC)
- 10:00 Dissecting phenotypic heterogeneity of human melanoma: building a rationale for active immunotherapies overcoming immunologically-induced dedifferentiation (ITEM)
- 10:20 Cancer evolution and identification of relapse-initiating cells (CEVIR)

#### Second Session

- 11:10 Fighting resistance in CLL (FIRE-CLL)
- 11:30 Genetic and cellular intratumor heterogeneity as predictor of chronic lymphocytic leukemia outcome and treatment resistance (GCH-CLL)
- 11:50 Defeating recurrence and resistance in AML: multigenomic approaches to analyse heterogeneity (DRAMA)
- 12:10 Multiple myeloma intra-clonal heterogeneity: evolution and implications of targeted therapy (IntraMMclo)

#### Third Session

- 13:30 Approaching recurrence and resistance mechanisms in esophagogastric adenocarcinomas from the prospective MEMORI trial (ARREST)
- 13:50 Targeting colon tumor initiating cell heterogeneity (TACTIC)
- 14:10 Evolution of resistant clones to novel target-directed drugs in colorectal tumors (INTRACOLOR)
- 14:30 Patient-derived models for intratumour functional heterogeneity and its implications for personalized medicine (BeFIT)
- 14:50 **Poster Session**

#### Fourth Session

- 16:00 Clinical utility of tumour heterogeneity in triple negative breast cancer and high-grade serous ovarian carcinoma for prediction of therapy response (TH4RESPONS)
- 16:20 Clinical impact of intratumor heterogeneity in metastatic breast cancer (CCE Breast)
- 16:40 Intratumour heterogeneity, clonal selection and metastatic propensity in breast cancer (HetMet)
- 17:00 Proteogenomic and targeted metabolomic analysis of ovarian cancer heterogeneity and its contribution to recurrence and therapy resistance (PROMETOV)
- 17:20 **Discussion: The impact and added value of transnational collaborations on cancer research**
- 18:20 **Networking dinner and poster prize ceremony**

**PARTICIPATION IS FREE OF CHARGE**

**Please register online by October 3rd:**



<https://forms.gle/Dg4knLwNLeU66kJe8>

#### Organising Committee:

- Dr. Liron Even-Faitelson, Chief Scientist Office, Israeli Ministry of Health, liron.ef@moh.gov.il
- Dr. Eva Batista, Ministry of Education, Science and Sport, Slovenia, Eva.Batista@gov.si
- Dr. Silvia Paradisi, National Institute of Health, Italy
- Mrs. Maria Romero, Ministry of Health, Italy

This project has received funding from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement No 643638